Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2012 August;60(4) > Minerva Cardioangiologica 2012 August;60(4):375-83

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  HEART FAILURE 

Minerva Cardioangiologica 2012 August;60(4):375-83

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Current therapeutic strategies in cardiorenal syndrome

Palazzuoli A., Geyer A., Malandrino A., Pellegrini M., Beltrami M., Gilleman M., Nuti R.

Department of Internal Medicine and Metabolic Diseases Cardiology Section, University of Siena, Siena, Italy


PDF


Cardiorenal syndromes (CRS) are disorders of the heart and kidneys in which an acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. Primary disorders of one of these two organs often result in secondary dysfunction or injury of the other. The lack of specific trials in this field highlights the need for further studies aimed to assess titration and appropriate dosages of drugs, according to both the etiology of chronic heart failure (CHF) and also the severity of underlying renal dysfunction. Moreover, the most recent clinical trials evaluating clinical and renal outcome in acute heart failure syndromes (AHFS), failed to demonstrate an improvement in renal function and perfusion. Therefore, Current American and European Guidelines for AHFS does not provide specific recommendation for patients with renal impairment. In this scenario several questions regarding the drugs, their recommended dosage and potential adverse effects on cardiac and renal outcome need to be addressed. Subsequently, therapy inducing an improvement in the renal function, a reduction of neurohormonal activation and an improvement of renal blood flow, could lead to a reduction in mortality and hospitalization in patients with CRS.

top of page